Gene Therapy For Severe Retinitis Pigmentosa Secures EMA PRIME Status

 
• By Neena Brizmohun

Janssen and MeiraGTx say their investigational product is the only treatment for x-linked retinitis pigmentosa in development to win a place on the European Medicines Agency’s priority medicines scheme.

Eye_DNA
The most frequent mutation causing x-linked retinitis pigmentosa is in the RPGR gene • Source: Shutterstock

More from R&D

More from Pink Sheet